US 12290598

An analysis of U.S. Patent 12,290,598 reveals the following details regarding the invention and its legal status.

Title: Orally administered corticosteroid compositions

Assignee: Ellodi Pharmaceuticals, L.P.

Inventors:

• Stephen Perrett
• Fredric Jay Cohen
• Gopi M. Venkatesh

Filing Date: January 5, 2022

Issue Date: Based on the information, the patent publication date is May 6, 2025.

Abstract:
The patent describes orally administered corticosteroid compositions designed for treating inflammatory conditions of the gastrointestinal tract. The invention also covers a method for treating these conditions by administering the described pharmaceutical compositions to an individual in need.

Overview of Independent Claims

This patent contains several independent claims, which define the core scope of the invention. In plain language, these claims protect:

Claim 1: A specific type of orally disintegrating tablet. This claim protects an orally disintegrating tablet that contains corticosteroid-containing granules and rapidly dispersing microgranules. The key features are the composition of these granules. The corticosteroid granules are made of the corticosteroid drug and a film-forming binder. The rapidly dispersing microgranules are composed of a disintegrant (like crospovidone) and a sugar alcohol or saccharide (like mannitol), with specific particle sizes to ensure they dissolve quickly in the mouth.

Claim 15: A method of making the orally disintegrating tablet. This claim protects the process for manufacturing the orally disintegrating tablets described in the patent. The method involves several steps: creating the corticosteroid-containing granules, preparing the rapidly dispersing microgranules, blending these with other ingredients like flavorings and sweeteners, and then compressing the mixture into tablets. A key aspect of this claimed method is the use of an external lubrication system during the tablet compression, which avoids mixing the lubricant directly into the tablet's composition.

Claim 20: A liquid pharmaceutical composition for oral administration. This claim protects a liquid formulation containing a corticosteroid. The distinctive feature of this composition is that it is substantially non-aqueous and includes a "bio-gelling polymer." This polymer causes the liquid to increase in viscosity, or turn into a gel, upon contact with the patient's gastrointestinal tract. This is intended to prolong the contact of the corticosteroid with the inflamed tissues.

A search of the U.S. Court of Appeals for the Federal Circuit (CAFC) dockets for 2026 did not yield any results for litigation involving this patent number. It is important to note that this patent is subject to a terminal disclaimer, which may limit its term to that of an earlier patent. The information presented here is based on the provided patent documentation and publicly available data as of the current date.